Research

Hormonal

Tirzepatide use in patients at increased risk of cardiovascular events does not increase the risk of serious adverse events or all-cause mortality compared to placebo, but significantly increases the risk of gastrointestinal non-serious adverse events.

If you are at high risk for heart issues, tirzepatide appears safe regarding serious complications like death or hospitalization, but you should expect stomach problems like nausea and diarrhea. These are common but usually not dangerous. Talk to your doctor about starting at a low dose to minimize these effects.

ModerateQualifiesMEDIUM confidence
Current evidence indicates that tirzepatide does not appear to influence the risk of serious adverse events... Tirzepatide use is associated with an increased risk of several gastrointestinal nsAEs.
Christina Dam Bjerregaard Sillassen et al. · BMC Medicine · 2026

Why this rating

Moderate certainty for SAEs, very low for mortality; high heterogeneity in non-serious events but consistent direction.

Source

The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis

Christina Dam Bjerregaard Sillassen et al. · BMC Medicine · 2026

DOI 10.1186/s12916-026-04824-w

Meta-analysis · 21 studies
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →